| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H23NO2 |
| Molecular Weight | 273.37 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C3=CC(C)=CC(C)=C3
InChI
InChIKey=HDDNYFLPWFSBLN-ZSHCYNCHSA-N
InChI=1S/C17H23NO2/c1-11-6-12(2)8-13(7-11)17(19)20-16-9-14-4-5-15(10-16)18(14)3/h6-8,14-16H,4-5,9-10H2,1-3H3/t14-,15+,16+
| Molecular Formula | C17H23NO2 |
| Molecular Weight | 273.37 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Forty-seven patients with common (n = 29) or classical (n = 8) migraine or mixed type with or without a psychogenic component (n = 10) received 20-40 mg Tropanserin (MDL-72,422) (n = 24) or placebo (n = 23) intravenously during the headache phase of a migraine attack.
Route of Administration:
Intravenous
